Logo image
Treatment of advanced and recurrent gynecologic cancer
Journal article   Open access   Peer reviewed

Treatment of advanced and recurrent gynecologic cancer

Luther W. Brady, Arnold M. Markoe, Timothy Deeulis and George C. Lewis
Cancer, v 60(S8), pp 2081-2093
15 Oct 1987
PMID: 3308068
url
https://doi.org/10.1002/1097-0142(19901015)60:8+<2081::aid-cncr2820601522>3.0.co;2-nView
Published, Version of Record (VoR)Maybe Open Access (Publisher Bronze) Open
url
https://doi.org/10.1002/1097-0142(19901015)60:8+<2081::AID-CNCR2820601522>3.0.CO;2-NView
Published, Version of Record (VoR) Open

Abstract

In 1986 73,400 new cases of invasive gynecologic cancer and 45,000 new cases of in situ carcinoma of the uterine cervix (about 9% of all cancers in women) were diagnosed in the US. A significant proportion of these patients die of local failure. In dealing with the wide variety of gynecologic cancers, extreme care must be used in choosing the appropriate treatment program for each problem. Therefore, the full extent of the disease at the time of initial presentation and recurrence must be determined. It is only with these data that appropriate treatment programs can be designed with the maximum potential for long‐term control or cure and with the minimum in treatment complication. There are no groups of disease processes like those seen in advanced or recurrent gynecologic cancer that offer such a challenge to the clinical practitioner.

Metrics

11 Record Views
13 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Logo image